Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Matthew Alef

Vascular Surgery Lebanon, NH Medical Doctor

NPI 1639371610 CMS profile 864954

1 Medical Center Dr, Fahc, Lebanon, NH 03756

Open in the dashboard

General payments

$24,824

61 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,917 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Matthew Alef of Lebanon, NH is reported in the CMS Open Payments database as having received $24,824 across 61 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,917 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,824 16
2024 General $7,075 31
2023 General $4,289 9
2022 General $6,636 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Alef
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Matthew Alef were reported at $6,824. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Matthew Alef Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $0 $348 $118–$1,110 $114
2021 $0 $471 $158–$1,421 $132
2022 $6,636 $725 $222–$2,183 $149
2023 $4,289 $836 $257–$2,440 $160
2024 $7,075 $909 $252–$2,619 $164
2025 $6,824 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Cook Incorporated $13,879 16 payments
  2. Penumbra, Inc. $3,908 3 payments
  3. Cook Medical LLC $3,309 28 payments
  4. Ge Healthcare $2,600 2 payments
  5. Bolton Medical Inc $259 2 payments
  6. Shape Memory Medical Inc. $187 3 payments
  7. W. L. Gore & Associates, Inc. $166 2 payments
  8. Endologix, Inc. $156 1 payment
  9. AngioDynamics, Inc. $116 1 payment
  10. Siemens Medical Solutions USA, Inc. $92 1 payment
  11. Other $152 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,940 6 payments
  2. Travel and Lodging $5,552 11 payments
  3. Food and Beverage $3,732 42 payments
  4. Consulting Fee $2,600 2 payments
Products named General payments · program years 2022–2025
  1. COOK $5,086 6 payments
  2. Indigo System $3,908 3 payments
  3. Zenith Alpha Aortic Intervention $3,691 14 payments
  4. Zilver PTX $2,720 4 payments
  5. Allia $2,600 2 payments
  6. Zenith Spiral-Z $1,802 7 payments
  7. ZENITH ALPHA Non SBU - Cook Management $1,125 4 payments
  8. ZENITH ALPHA Aortic Intervention $299 2 payments
  9. TREO ABDOMINAL STENT-GRAFT SYSTEM $259 2 payments
  10. IMPEDE EMBOLIZATION PLUG $187 3 payments
  11. Other $1,333 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

73

Median for Vascular Surgery: 122

Drug cost

$12,273

Median for Vascular Surgery: $14,135

Branded share of claims

84.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 17 $11,774
Clopidogrel Clopidogrel Bisulfate Brand 45 $415
Atorvastatin Calcium Generic 11 $84

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$87,290

Medicare's payments for the services billed

Medicare patients

494

Average age 74

Services billed

819

213 women, 281 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 47%
Diabetes 35%
Chronic kidney disease 30%
Heart failure 27%
Atrial fibrillation 27%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record